Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing pre-clinical studies of Serina’s lead drug candidate SER-252 (POZ-apomorphine) for treatment of Parkinson’s Disease, and expanding POZ Platform.
Lead Product(s): POZ-Apomorphine
Therapeutic Area: Neurology Product Name: SER-252
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: AgeX Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger March 26, 2024
Details:
The agreement provides access to Serina's POZ polymer technology for potential use in lipid nanoparticle (LNP) formulations for RNA-based therapeutics.
Lead Product(s): RNA-based Therapeutic
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 17, 2023